Skin Rash
10
0
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
10.0%
1 terminated out of 10 trials
87.5%
+1.0% vs benchmark
20%
2 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)
GI Symptoms in Infants Fed Goat Milk-based Infant Formula
Evaluation of a Comprehensive School Health Programme in Zambia
National Trends in Otitis Media in Children Under 5 Years of Age
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation